Funding News Edition: December 15, 2021 See more articles in this edition
If you are a researcher who can advance our understanding of the etiology and pathogenesis of celiac disease research, apply for funds through the Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research. NIAID participates in this NOSI alongside three other NIH institutes and centers (ICs): National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Research Objectives
Clinical manifestations of celiac disease are multifaceted, and its pathogenesis can involve a combination of predisposing genes, gluten, and environmental factors. While many aspects of the underlying mechanism are well understood, there remains an unmet need in understanding celiac disease pathogenesis, including a limited understanding of pathways of disease and tissue destruction, and the cause of tolerance loss to a component of food.
This NOSI encourages research applications that include the following NIAID-relevant research topics:
- Underlying mechanisms of loss of oral tolerance
- Autoimmune triggers in celiac disease
- Strategies that can eliminate and revert the pathogenic memory gluten-specific CD4 memory T cells
- Cellular circuits and mechanisms involved in tissue destruction
- The role of microbiota in the loss of oral tolerance and tissue destruction
- The discovery of immune modulating interventions and strategies to prevent celiac disease and/or restore tolerance
- Biomarkers that predict tissue destruction in celiac disease
- Determining what makes gluten a harmful dietary antigen that can cause tissue destruction
- Developmental triggers of inflammatory T helper-1 responses to a dietary antigen
- The link between tissue destruction and loss of tolerance
- Common pathogenic mechanisms between celiac disease and other complex immune disorders
- Novel animal models or in vitro models using samples from people with celiac disease that mimic its immunopathology
- The role of gastrointestinal immune response in the development of extraintestinal complications of celiac disease
IC-Specific Application and Submission Information
Applicants must select an IC and an associated funding opportunity announcement (FOA) to apply in response to this NOSI. The selection must align with the IC requirements listed to be considered responsive to that FOA. Nonresponsive applications will be withdrawn from consideration for this initiative.
This notice pertains to due dates on or after January 12, 2022, and subsequent receipt dates through January 7, 2025.
|
FOA |
Title |
First Available Due Date |
Participating ICs |
|
NIH Research Project Grant (Parent R01, Clinical Trial Required) |
February 5, 2022 |
NCCIH |
|
|
NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed) |
February 5, 2022 |
NIAID, NCCIH, NCI, NIAMS |
|
|
NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Required) |
February 16, 2022 |
NCCIH |
|
|
NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed) |
February 16, 2022 |
NIAID |
|
|
NIH Small Research Grant Program (Parent R03, Clinical Trial Not Allowed) |
February 16, 2022 |
NIAID, NCCIH, NCI, NIAMS |
|
|
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03, Clinical Trial Optional) |
February 24, 2022 |
NCI |
|
|
National Cancer Institute Program Project Applications (P01, Clinical Trial Optional) |
January 25, 2022 |
NCI |
|
|
NCCIH Natural Product Early Phase Clinical Trial Award (R33, Clinical Trial Required) |
June 1, 2022 |
NCCIH |
|
|
NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33, Clinical Trial Required) |
June 1, 2022 |
NCCIH |
|
|
NIAID Clinical Trial Planning Grant (R34, Clinical Trial Not Allowed) |
January 12, 2022 |
NIAID |
|
|
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01, Clinical Trial Required) |
February 5, 2022 |
NCI |
|
|
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44, Clinical Trial Required) |
January 14, 2022 |
NIAID |
|
|
NIAID Clinical Trial Implementation Cooperative Agreement (U01, Clinical Trial Required) |
January 14, 2022 |
NIAID |
Applicants must follow all instructions in the SF 424 (R&R) Application Guide and the FOA used for submission as well as include “NOT-AI-22-004” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form to be considered for funding. NIAID will not consider applications that do not have this information in box 4B.
Contact Information
Direct all inquiries to Dr. Annette L. Rothermel, NIAID’s scientific/research contact listed for this initiative, at 240-627-3477 or arothermel@niaid.nih.gov.